Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma
Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma
复制标题
C-Kit 阳性转移性软组织平滑肌肉瘤患者对甲磺酸伊马替尼作为二线治疗缺乏反应
DOI：
10.1177/030089160509100123
复制
发表时间：
2005
期刊：
影响因子：
1.9
通讯作者：
A. Santoro
中科院分区：
文献类型：
--
作者：
N. Silvestris;H. S. Parra;F. Angelini;S. Di Cosimo;M. D'aprile;A. Santoro
Today, the gold standard for treatment of metastatic sarcoma still resides in the combination of an anthracycline and ifosfamide, with a response rate of around 25%; few chemotherapy agents are active as secondline treatment1. Imatinib mesylate (formerly STI571, Gleevec®), a selective inhibitor of the BCR-ABL tyrosine kinase (TK), is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors expressing the TK receptor c-kit2 . This drug interferes with the growth of c-kit-positive Ewing's sarcoma and small cell lung cancer cell lines, as shown in in vitro and in vivo studies3•4 . To the best of our knowledge, the case described here is the fifth case reported in the literature of advanced c-kit-positive leiomyosarcoma treated with imatinib mesylate after combination therapy with epirubicin and ifosfamide had failed5 . In October 2002, a 53-year-old man was admitted to our unit because of the appearance of a nodule located in the left parascapular region. A computed tomography (CT) scan of the chest showed a large inhomogeneous neoformation in the same region. The mass was radically resected. Following microscopic and immunohistochemical examination, a diagnosis of soft-tissue leiomyosarcoma was made. A subsequent CT scan of the chest revealed the presence of two small nodules in the right lung. Four cycles of combination chemothera-
